Spain Nicotine Replacement Therapy Market Overview,2030

The nicotine replacement therapy (NRT) market in Spain has developed gradually within the broader context of high smoking prevalence, cultural norms, and evolving tobacco control policies. Spain has one of the largest smoking populations in Europe, with about 22% of adults smoking daily in 2023, translating to over 9 million smokers. NRT was first introduced in Spain in the early 1990s, primarily in the form of nicotine gum and patches available through pharmacies. For years, adoption was limited due to the lack of reimbursement and relatively low awareness compared to countries such as France or the UK. The Spanish government’s 2005 ban on smoking in enclosed public spaces and the more comprehensive 2011 “Ley Antitabaco” (Anti-Tobacco Law) created momentum for smoking cessation programs, boosting NRT adoption. However, it was only in 2020 that Spain implemented limited public reimbursement for NRT, covering prescription-based products such as patches and chewing gums for certain populations through the National Health System (SNS). This marked a significant policy shift that increased uptake, especially among lower-income smokers. The Spanish NRT market is currently valued at approximately EUR 200–300 million, dominated by patches and gums distributed through pharmacies. Public awareness campaigns such as “Año Sin Tabaco” and the EU-backed “Ex-Smokers are Unstoppable” initiative have further supported growth. Despite these advances, cultural attitudes toward smoking, particularly its social acceptance in hospitality settings, continue to limit cessation efforts. As a result, Spain’s NRT market is positioned as underpenetrated relative to smoking prevalence, with considerable room for expansion through stronger policy and reimbursement support.

According to the research report ""Spain Nicotine Replacement Therapy Market Overview, 2030,"" published by Bonafide Research, the Spain Nicotine Replacement Therapy market is anticipated to grow at 16.31% CAGR from 2025 to 2030.Spain presents substantial opportunities for NRT expansion, particularly in light of its high smoking prevalence, recent reimbursement policies, and alignment with EU tobacco control objectives. Regulatory oversight is managed by the Spanish Agency of Medicines and Medical Devices (AEMPS), which ensures pharmaceutical-grade standards for NRT. Since 2020, prescription-based reimbursement through the SNS has improved affordability, though coverage is limited to certain populations and product types. Market opportunities lie in expanding this reimbursement framework to include broader NRT formats such as oral sprays and lozenges, which remain largely out-of-pocket purchases. Trends indicate rising demand for fast-acting formulations, as Spanish smokers tend to favor short-term aids during quit attempts. Combination therapy, involving patches alongside gums or lozenges, is being increasingly recommended in clinical guidelines. Digital health integration, including apps and teleconsultations linked to NRT prescriptions, represents a growing innovation area, particularly post-COVID. Competition from e-cigarettes is strong: Spain has a vaping population exceeding 1.5 million, with vape shops widely spread across urban centers. While not endorsed by public health authorities, e-cigarettes are viewed by many consumers as cheaper alternatives to NRT, creating a perception challenge. Strategic recommendations include strengthening awareness campaigns that emphasize NRT’s medical safety, leveraging pharmacy networks to expand counseling, and developing affordable subscription-based options for younger demographics. Expanding the scope of SNS reimbursement and integrating NRT into broader anti-tobacco programs would significantly increase market penetration. With Spain targeting a smoke-free generation by 2035 under EU policy frameworks, NRT will remain central to cessation strategies, offering strong growth potential if affordability and accessibility challenges are addressed.

Spain’s nicotine alternatives market is segmented into NRT, e-cigarettes, and heat-not-burn tobacco products, reflecting competing pathways for smokers. NRT remains the only medically validated option, with patches and gums accounting for the majority of sales through pharmacies. Leading brands include Nicorette (Johnson & Johnson), NiQuitin (Perrigo), and various local generics, supported by prescription-based reimbursement for select products. Despite this, adoption is modest relative to smoking prevalence, partly due to limited reimbursement and strong competition from consumer-driven alternatives. E-cigarettes have grown rapidly, with Spain ranking among the EU’s largest vaping markets. Approximately 1.5–2 million adults regularly vape, supported by a dense network of vape shops and rising popularity of disposable devices such as Elf Bar and Vuse. Although Spanish regulators do not classify e-cigarettes as cessation tools, consumer adoption has outpaced NRT usage, particularly among younger demographics. Heat-not-burn products, led by Philip Morris International’s IQOS, have also established a strong presence since their 2016 introduction in Spain, especially in Madrid and Barcelona. These products appeal to middle-income consumers seeking a premium alternative, though their market share remains smaller than that of vaping. This three-way segmentation highlights NRT’s challenge: while it retains clinical credibility and limited state reimbursement, consumer preference is shifting toward vaping and heated tobacco as modern, socially integrated alternatives. For NRT to remain competitive, it must emphasize its medical validation, expand formats beyond patches and gums, and increase accessibility through subsidies and innovative delivery methods tailored to Spanish consumers.

The Spanish NRT market is split between over-the-counter (OTC) and prescription-based sales, though OTC has historically dominated. Pharmacies serve as the primary retail channel, with gums, lozenges, and patches widely available for purchase without prescriptions. These products appeal to smokers making self-directed quit attempts, offering convenience and privacy. Prescription-based sales, however, have gained importance since the 2020 SNS reimbursement policy, which covers specific products like nicotine patches and chewing gums for eligible smokers. Under this system, prescriptions from general practitioners allow partial or full reimbursement, making NRT more accessible for economically disadvantaged groups. This shift has boosted prescription uptake, particularly in urban areas where awareness of the policy is higher. Nonetheless, OTC sales remain strong, supported by brand familiarity and the broad pharmacy network. Recent trends suggest convergence between the two models, with some online pharmacies now offering prescription fulfillment alongside traditional OTC sales. One key challenge is limited awareness of reimbursement options, which restricts prescription uptake outside of major cities. Strategic improvements include expanding public communication about reimbursement availability and broadening coverage to include more NRT formats. Currently, OTC remains the backbone of the Spanish market, but prescription-based sales are expected to grow steadily as reimbursement policies mature. This dual structure reflects Spain’s gradual transition toward a mixed system, balancing convenience with affordability. Strengthening the prescription channel through wider reimbursement and awareness campaigns will be essential for increasing NRT adoption among Spain’s large smoking population.

NRT distribution in Spain is dominated by offline channels, particularly the extensive pharmacy network of more than 22,000 outlets nationwide. Pharmacies not only stock NRT products but also serve as critical health intermediaries, offering counseling and prescription services linked to SNS reimbursement. Supermarkets and convenience stores play a minor role, generally limited to gums and lozenges. Hospitals and specialized cessation clinics also contribute, particularly for prescription-based distribution. Offline channels benefit from strong cultural trust in pharmacists and the face-to-face healthcare model prevalent in Spain. Online distribution has expanded in recent years, accelerated by the COVID-19 pandemic and increasing consumer demand for home delivery and privacy. Licensed online pharmacies such as PromoFarma and DosFarma have gained traction, offering both OTC sales and prescription-linked fulfillment. Subscription-based models for patches and gums are emerging, targeting younger, digitally engaged consumers. Despite this growth, online sales still account for a small fraction of the market compared to offline channels, as regulatory requirements and consumer habits favor in-person pharmacy interactions. The government also maintains strict controls over online pharmaceutical sales to ensure compliance with safety standards. Over the next decade, online channels are expected to grow at a faster rate than offline, though pharmacies will remain dominant due to their integration into the reimbursement system and established trust. This dual distribution system ensures broad access while gradually shifting toward digital convenience, reflecting broader e-health adoption trends in Spain’s healthcare system.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Nicotine Replacement Therapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Nicotine Replacement Therapy
• E-cigarettes
• Heat-not-burn tobacco products
By Nicotine Replacement Therapy
• Nicotine Gums
• Nicotine Lozenges
• Nicotine Nasal Sprays
• Nicotine Pouches
• Others (Nicotine Patches, Nicotine Inhalers & Others)
By Sales Type
• Over-the-Counter (OTC)
• Prescription-Based

By Distribution Channel
• Offline
• Online
Show more